Teresa Magnes
Salzburg, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.
Journal: Anticancer research
Published: January 05, 2023
The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms.
Journal: International journal of molecular sciences
Published: July 09, 2021
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.
Journal: International journal of molecular sciences
Published: March 28, 2021
Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.
Journal: Future science OA
Published: January 13, 2021
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.
Journal: Cancers
Published: January 11, 2021
Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.
Journal: Wiener klinische Wochenschrift
Published: November 17, 2020
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
Journal: ESMO open
Published: October 06, 2020
Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.
Journal: Journal of clinical medicine
Published: April 26, 2020
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
Journal: European journal of haematology
Published: October 18, 2019
C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling overall survival Prediction in Pancreatic Cancer Patients.
Journal: Journal of clinical medicine
Published: September 25, 2019
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Journal: European journal of haematology
Published: January 28, 2019
Last Updated: 09/26/2026